Hope Medicine (HopeMed) is a clinical-stage biopharmaceutical company founded on research from Professor Rui-Ping Xiao's lab at Peking University. With R&D bases in Beijing, Shanghai, and Nanjing, the company develops innovative therapies for endocrine, cardiovascular, and metabolic diseases with a focus on women's health. HopeMed's lead asset HMI-115 targets the prolactin receptor under a worldwide exclusive license from Bayer AG.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2024
May 2021
Apr 2019
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
